 <h1>Cabergoline Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to cabergoline: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, cabergoline may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking cabergoline:</p><p>
<i>Less common</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>dizziness, faintness, or lightheadedness when getting up from lying or sitting position</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>general feeling of discomfort or illness</li>
<li>rapid weight gain</li>
<li>swelling around the eyes</li>
<li>tingling of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chest pain or tightness</li>
<li>continuing loss of appetite</li>
<li>continuing or severe abdominal or stomach pain</li>
<li>continuing or severe nausea and vomiting</li>
<li>cough</li>
<li>decreased ability to exercise</li>
<li>fever</li>
<li>increased frequency of urination</li>
<li>loss of appetite</li>
<li>lower abdominal or stomach pain</li>
<li>lower back pain</li>
<li>nausea</li>
<li>trouble breathing</li>
<li>vomiting</li>
<li>weakness</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking cabergoline:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Fainting</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>stuffy nose</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of cabergoline may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement (stool)</li>
<li>dizziness</li>
<li>excess air or gas in the stomach or intestines</li>
<li>full feeling</li>
<li>headache</li>
<li>lack or loss of strength</li>
<li>passing gas</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>acid or sour stomach</li>
<li>anxiety</li>
<li>belching</li>
<li>blemishes on the skin</li>
<li>breast pain</li>
<li>burning, itching, or stinging of the skin</li>
<li>changes in vision</li>
<li>cramps</li>
<li>depression</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dry mouth or toothache</li>
<li>feeling of constant movement of self or surroundings</li>
<li>feeling of warmth</li>
<li>gas</li>
<li>heartburn</li>
<li>heavy bleeding</li>
<li>indigestion</li>
<li>itching skin</li>
<li>joint pain</li>
<li>muscle aches and pains</li>
<li>muscle stiffness</li>
<li>pimples</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>runny nose</li>
<li>sensation of spinning</li>
<li>shivering</li>
<li>sleepiness or unusual drowsiness</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stomach discomfort or upset</li>
<li>sudden sweating</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloody nose</li>
<li>difficulty in concentrating</li>
<li>increased in sexual ability, desire, drive, or performance</li>
<li>increased interest in sexual intercourse</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Attack, assault, or force</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>hair loss or thinning of the hair</li>
<li>pathological gambling</li>
<li>severe mood or mental changes</li>
<li>unusual behavior</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cabergoline: oral tablet</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 29%)</p>
<p><b>Common</b> (1% to 10%): Constipation, dyspepsia, gastritis, vomiting, abdominal pain, dyspepsia, dry mouth, diarrhea, flatulence, throat irritation, toothache<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%), dizziness (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Dizziness/vertigo, dyskinesia, paresthesia, somnolence</p>
<p><b>Uncommon</b> (0.1% to 1%): Hyperkinesia</p>
<p><b>Frequency not reported</b>: Sudden sleep onset, syncope, tremor<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatigue, malaise<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucinations sleep disturbance, increased libido, confusion, depression, anxiety, insomnia, nervousness</p>
<p><b>Uncommon</b> (0.1% to 1%): Delusions, psychotic disorder</p>
<p><b>Frequency not reported</b>: Aggression, hypersexuality, pathological gambling<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema</p>
<p><b>Common</b> (1% to 10%): Angina (with concomitant levodopa use), postural hypotension, hot flashes, cardiac valvulopathy, hypotension, dependent edema, palpitation</p>
<p><b>Uncommon</b> (0.1% to 1%): Erythromelalgia</p>
<p><b>Rare</b> (less than 0.1%): Syncope, heart failure </p>
<p><b>Frequency not reported</b>: Constrictive pericarditis, digital vasospasm</p>
<p><b>Postmarketing reports</b>: Cardiac valvulopathy, pericarditis, pericardial effusion<sup>[Ref]</sup></p><p>Reports of cardiac valvulopathy have generally been received in patients on higher doses (greater than 2 mg/day); however, there have been cases in patients receiving lower doses for the treatment of hyperprolactinemic disorders.  In a multi-country, retrospective cohort study, record review looking for an association between the new use of dopamine agonists (including this drug; n=27,812) and cardiac valvular regurgitation (CVR), other fibrosis, and other cardiopulmonary events found an increased risk of CVR among patients with Parkinson's disease when compared to non-ergot derived dopamine agonists and levodopa.  Analysis in patients with hyperprolactinemia treated with this drug (n=8386) found that compared to non-users, exposed persons did not have an elevated risk of CVR.  These findings are consistent with other published studies.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Leg cramps<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, acne, pruritus </p>
<p><b>Frequency not reported</b>: Alopecia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p>
<p><b>Uncommon</b> (0.1% to 1%): Pleural effusion, pulmonary fibrosis, rhinitis</p>
<p><b>Very rare</b> (less than 0.01%): Fibrosis (including pleural fibrosis)</p>
<p><b>Frequency not reported</b>: Respiratory disorder, respiratory failure, pleuritic, chest pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Periorbital edema, abnormal vision<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Breast pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysmenorrhea<sup>[Ref]</sup></p><h3>General</h3><p>Adverse effects are generally dose related.  At lower doses, the more commonly reported adverse reactions included nausea, headache, dizziness/vertigo, abdominal pain/dyspepsia/gastritis, asthenia/fatigue; at higher doses, additional events of valvulopathy, dyspnea, dyskinesia, orthostatic hypotension, hallucination, and constipation have been commonly reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic function abnormalities</p>
<p><b>Postmarketing reports</b>: Liver function test abnormal<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_3">3. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about cabergoline</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>87 Reviews</li>
<li>Drug class: prolactin inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cabergoline &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Dostinex</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hyperprolactinemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to cabergoline: oral tablet</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 29%)</p><p><b>Common</b> (1% to 10%): Constipation, dyspepsia, gastritis, vomiting, abdominal pain, dyspepsia, dry mouth, diarrhea, flatulence, throat irritation, toothache<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 26%), dizziness (up to 17%)</p><p><b>Common</b> (1% to 10%): Dizziness/vertigo, dyskinesia, paresthesia, somnolence</p><p><b>Uncommon</b> (0.1% to 1%): Hyperkinesia</p><p><b>Frequency not reported</b>: Sudden sleep onset, syncope, tremor<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Asthenia</p><p><b>Uncommon</b> (0.1% to 1%): Fatigue, malaise<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucinations sleep disturbance, increased libido, confusion, depression, anxiety, insomnia, nervousness</p><p><b>Uncommon</b> (0.1% to 1%): Delusions, psychotic disorder</p><p><b>Frequency not reported</b>: Aggression, hypersexuality, pathological gambling<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Peripheral edema</p><p><b>Common</b> (1% to 10%): Angina (with concomitant levodopa use), postural hypotension, hot flashes, cardiac valvulopathy, hypotension, dependent edema, palpitation</p><p><b>Uncommon</b> (0.1% to 1%): Erythromelalgia</p><p><b>Rare</b> (less than 0.1%): Syncope, heart failure </p><p><b>Frequency not reported</b>: Constrictive pericarditis, digital vasospasm</p><p><b>Postmarketing reports</b>: Cardiac valvulopathy, pericarditis, pericardial effusion<sup>[Ref]</sup></p><p>Reports of cardiac valvulopathy have generally been received in patients on higher doses (greater than 2 mg/day); however, there have been cases in patients receiving lower doses for the treatment of hyperprolactinemic disorders.  In a multi-country, retrospective cohort study, record review looking for an association between the new use of dopamine agonists (including this drug; n=27,812) and cardiac valvular regurgitation (CVR), other fibrosis, and other cardiopulmonary events found an increased risk of CVR among patients with Parkinson's disease when compared to non-ergot derived dopamine agonists and levodopa.  Analysis in patients with hyperprolactinemia treated with this drug (n=8386) found that compared to non-users, exposed persons did not have an elevated risk of CVR.  These findings are consistent with other published studies.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Leg cramps<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Rash, acne, pruritus </p><p><b>Frequency not reported</b>: Alopecia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea</p><p><b>Uncommon</b> (0.1% to 1%): Pleural effusion, pulmonary fibrosis, rhinitis</p><p><b>Very rare</b> (less than 0.01%): Fibrosis (including pleural fibrosis)</p><p><b>Frequency not reported</b>: Respiratory disorder, respiratory failure, pleuritic, chest pain<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Periorbital edema, abnormal vision<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Breast pain</p><p><b>Uncommon</b> (0.1% to 1%): Dysmenorrhea<sup>[Ref]</sup></p><h3>General</h3><p>Adverse effects are generally dose related.  At lower doses, the more commonly reported adverse reactions included nausea, headache, dizziness/vertigo, abdominal pain/dyspepsia/gastritis, asthenia/fatigue; at higher doses, additional events of valvulopathy, dyspnea, dyskinesia, orthostatic hypotension, hallucination, and constipation have been commonly reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Hepatic function abnormalities</p><p><b>Postmarketing reports</b>: Liver function test abnormal<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reaction<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Multum Information Services, Inc. Expert Review Panel"  </p><p id="ref_3">3. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI. </p><h2>More about cabergoline</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>87 Reviews</li>
<li>Drug class: prolactin inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Cabergoline &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hyperprolactinemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>